Top

Published in:

01-10-2007 | Review Article

Individualising Therapy for Older Adults with Diabetes Mellitus

Authors: Danelle Cayea, Cynthia Boyd, Dr Samuel C. Durso

Published in: Drugs & Aging | Issue 10/2007

Abstract

The goal when treating patients with diabetes mellitus is to achieve the maximum longevity consistent with an optimal quality of life. To achieve this goal, treatment is typically focused on management of hyperglycaemic symptoms and prevention of microvascular and macrovascular complications. While appropriate for most individuals, including many older adults with robust health, this focus is often too limited for older adults facing diminished life expectancy and co-existing medical illness, frailty and disability. Creating a treatment plan that optimises health and function, and reduces the risk for morbidity and mortality, requires individualised therapy that judiciously manages symptoms and multiple competing health risks while remaining consistent with the patient’s or his/her caregiver’s healthcare preferences. Physicians caring for older adults with diabetes must be adept at recognising conditions commonly associated with diabetes, including the interplay with co-morbid illness, and be able to assess the patient’s health status and use this information to recommend a treatment plan that is consistent with the patient’s personal goals for care.

The majority of older adults with diabetes will benefit from management of cardiovascular risk, including intensive management of hypertension, lipids, use of aspirin (acetylsalicylic acid) and smoking cessation, and screening for common geriatric syndromes. For a significant minority of older adults with life expectancy of ≥10 years, it is reasonable to consider intensive management of hyperglycaemia (glycosylated haemoglobin [HbA_1c] target ≤7%). For frail older adults with life expectancy of ≤5 years, strategies for reducing medical burden, improving function and moderate glucose control (HbA_1c ≈8%) is reasonable and sufficient to control hyperglycaemic symptoms.

Sinclair A. Clinical guidelines for type 2 diabetes mellitus. European Diabetes Working Party for Older People, 2001–2004 [online]. Available from URL: http://www.eugms.org/documents/clinicalguidelinediabetes.pdf [Accessed 2007 Aug 23]

Park E, Durso SC, Confessore GJ. A case study of educational practices for the aging global population. Lifelong Educ Lib 2006; 6: 67–79

Landefeld CS, Callahan CM, Woolard N. General internal medicine and geriatrics: building a foundation to improve the training of general internists in the care of older adults. Ann Intern Med 2003; 139(7): 609–14PubMed

National Diabetes Information Clearinghouse. National diabetes statistics [online]. Available from URL: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm [Accessed 2007 Aug 23]

Durso SC. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA 2006; 295(16): 1935–40PubMedCrossRef

Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51 (5 Suppl. Guidelines): S265–80PubMedCrossRef

Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000; 320(7246): 1380–4PubMedCrossRef

Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000; 320(7231): 341–6PubMedCrossRef

Arora NK, McHorney CA. Patient preferences for medical decision making: who really wants to participate? Med Care 2000; 38(3): 335–41PubMedCrossRef

10.

Say RE, Thomson R. The importance of patient preferences in treatment decisions: challenges for doctors. BMJ 2003; 327(7414): 542–5PubMedCrossRef

11.

Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA 2004; 291(19): 2359–66PubMedCrossRef

12.

Vijan S, Hayward RA, Ronis DL, et al. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 2005; 20(5): 479–82PubMedCrossRef

13.

Huang ES, Gorawara-Bhat R, Chin MH. Self-reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc 2005; 53(2): 306–11PubMedCrossRef

14.

Maddigan SL, Feeny DH, Majumdar SR, et al. Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 2006; 96(9): 1649–55PubMedCrossRef

15.

Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 2005; 14(5): 1311–20PubMedCrossRef

16.

Deaton C, Kimble LP, Veledar E, et al. The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status. Heart Lung 2006; 35(5): 315–23PubMedCrossRef

17.

Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162(20): 2269–76PubMedCrossRef

18.

Niefeld MR, Braunstein JB, Wu AW, et al. Preventable hospitalization among elderly Medicare beneficiaries with type 2 diabetes. Diabetes Care 2003; 26(5): 1344–9PubMedCrossRef

19.

Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood) 2001; 20(6): 233–41CrossRef

20.

Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006; 29(3): 725–31PubMedCrossRef

21.

Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294(6): 716–24PubMedCrossRef

22.

Standards of medical care in diabetes: 2006. Diabetes Care 2006; 29Suppl. 1: 4–42

23.

Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004; 61(10): 1042–9PubMedCrossRef

24.

Harman JS, Edlund MJ, Fortney JC, et al. The influence of comorbid chronic medical conditions on the adequacy of depression care for older Americans. J Am Geriatr Soc 2005; 53(12): 2178–83PubMedCrossRef

25.

Fenton JJ, Von Korff M, Lin EH, et al. Quality of preventive care for diabetes: effects of visit frequency and competing demands. Ann Fam Med 2006; 4(1): 32–9PubMedCrossRef

26.

Wray LA, Ofstedal MB, Langa KM, et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci 2005; 60(9): 1206–11PubMedCrossRef

27.

Volpato S, Blaum C, Resnick J, et al. Comorbidities and impairments explaining the association between diabetes and lower extremity disability: the Women’s Health and Aging Study. Diabetes Care 2002; 25(4): 678–83PubMedCrossRef

28.

Blaum CS, Ofstedal MB, Langa KM, et al. Functional status and health outcomes in older Americans with diabetes mellitus. J Am Geriatr Soc 2003; 51(6): 745–53PubMedCrossRef

29.

Volpato S, Ferrucci L, Blaum C, et al. Progression of lower-extremity disability in older women with diabetes: the Women’s Health and Aging Study. Diabetes Care 2003; 26(1): 70–5PubMedCrossRef

30.

Covinsky KE, Hilton J, Lindquist K, et al. Development and validation of an index to predict activity of daily living dependence in community-dwelling elders. Med Care 2006; 44(2): 149–57PubMedCrossRef

31.

Maty SC, Fried LP, Volpato S, et al. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci 2004; 59(2): 148–53PubMedCrossRef

32.

Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154(7): 635–41PubMedCrossRef

33.

Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61(5): 661–6PubMedCrossRef

34.

Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology 1999; 52(5): 971–5PubMedCrossRef

35.

Feil D, Weinreb J, Sultzer D. Psychiatric disorders and psychotropic medication use in elderly persons with diabetes. Ann Long Term Care 2006; 14(7): 39–47

36.

Brown JS, Vittinghoff E, Lin F, et al. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001–2002. Diabetes Care 2006; 29(6): 1307–12PubMedCrossRef

37.

Volpato S, Leveille SG, Blaum C, et al. Risk factors for falls in older disabled women with diabetes: the Women’s Health and Aging Study. J Gerontol A Biol Sci Med Sci 2005; 60(12): 1539–45PubMedCrossRef

38.

Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002; 324(7353): 1577–80PubMedCrossRef

39.

Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285(21): 2750–6PubMedCrossRef

40.

Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295(7): 801–8PubMedCrossRef

41.

Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 138(3): 215–29PubMed

42.

Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138(7): 593–602PubMed

43.

Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140(8): 650–8PubMed

44.

Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29(7): 1478–85PubMedCrossRef

45.

Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238–48PubMedCrossRef

46.

Tinetti ME. Clinical practice: preventing falls in elderly persons. N Engl J Med 2003; 348(1): 42–9PubMedCrossRef

47.

Tinetti ME, Doucette J, Claus E, et al. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995; 43(11): 1214–21PubMed

48.

Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331(13): 821–7PubMedCrossRef

49.

Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16(5): 468–74PubMedCrossRef

50.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53

51.

Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; (1): CD002967

52.

Black J, Cefalu CA, Durso SC, et al. Diabetes mellitus: oral antidiabetic agents, insulin, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and calcium channel blockers. In: Geriatric pharmaceutical care guidelines: a clinical and cost reference tool for use in geriatric care. Covington (KY): Omnicare, 2005: 185–204

53.

Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137(1): 25–33PubMed

54.

Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust 2004; 180(2): 53–4PubMed

55.

Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326(7379): 4–5PubMedCrossRef

56.

van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50(6): 735–41PubMedCrossRef

57.

Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157(15): 1681–6PubMedCrossRef

58.

Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33(4): 278–85PubMed

59.

Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005; 28(7): 601–31PubMedCrossRef

60.

Greco D, Angileri G. Drug-induced severe hypoglycaemia in type 2 diabetic patients aged 80 years or older. Diabetes Nutr Metab 2004; 17(1): 23–6PubMed

61.

Physicians’ desk reference (2004). 58th ed. Montvale (NJ): Thomson PDR, 2004: 718–20, 742–3, 2603–4

62.

Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complicat 2004; 18(1): 60–8PubMedCrossRef

63.

Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44(7): 751–5PubMed

64.

Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17(6): 467–73PubMedCrossRef

65.

US FDA. Code of federal regulations. Title 21, Volume 5. Subpart E: Requirements for specific new drugs or devices. Sec. 310.517: labeling for oral hypoglycemic drugs of the sulfonylurea class [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFR-Search.cfm?fr=310.517 [Accessed 2007 23 Aug]

66.

Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging 2005; 22(3): 209–18PubMedCrossRef

67.

Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006; 55 (5 Suppl. 1): S16–9PubMedCrossRef

68.

Del Prato S, Heine RJ, Keilson L. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care 2003; 26(7): 2075–80PubMedCrossRef

69.

Papa G, Fedele V, Rizzo MR. Safety of type 2 diabetes treatment with epaglinide compared with glibenclamide in elderly people. Diabetes Care 2006; 29: 1918–20PubMedCrossRef

70.

Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67(1): 7–15PubMedCrossRef

71.

Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Comparative effectiveness review No. 8 prepared by Johns Hopkins Evidence-based Practice Center under contract No. 209-02-0018. Rockville (MD). Agency for Healthcare Research and Quality, 2007 Jul [online]. Available from URL: http://effectivehealthcare.ahrq.gov/repFiles/OralFullReport.pdf [Accessed 2007 Aug 23]

72.

Abramowicz M, Zuccotti G. Drugs for diabetes. Treat Guidel Med Lett 2005 Aug; 3(36): 57–62PubMed

73.

Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27(1): 256–63PubMedCrossRef

74.

US FDA. GlaxoSmithKline letter [online]. Available from URL: http://www.fda.gov/medwatch/safety/2006/Avandia_DHCPletter.pdf [Accessed 2006 Nov 21]

75.

Beebe K, Patel J. Rosiglitazone is effective and well-tolerated in patients ≥65 years with type 2 diabetes [abstract]. Diabetes 1999; 42(SI): A111

76.

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–89PubMedCrossRef

77.

Isley WL. Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. ACP J Club 2006; 144(2): 34PubMed

78.

Willms B, Rugge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 751–66CrossRef

79.

Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98(5): 443–51PubMedCrossRef

80.

De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7(1): 73–82PubMedCrossRef

81.

Inhaled insulin (Exubera). Med Lett Drugs Ther 2006; 48(1239): 57–8

82.

DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28(8): 1922–8PubMedCrossRef

83.

Quattrin T, Belanger A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622–7PubMedCrossRef

84.

Rosenstock J, Cappelleri JC, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 2013–8

85.

Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47(1210): 45–6

86.

Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60(11): 1454–70PubMedCrossRef

Title: Individualising Therapy for Older Adults with Diabetes Mellitus
Authors: Danelle Cayea
Cynthia Boyd
Dr Samuel C. Durso
Publication date: 01-10-2007
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 10/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200724100-00005

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2007

Advances in Pneumococcal Vaccines

Treatment Strategies in Elderly Patients with Multiple Myeloma

Bleeding Peptic Ulcer in the Elderly

Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer

Getting Better, Getting Well

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials